WTX-330

Biologic (subtype unspecified)

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Advanced Solid Tumors and Non-Hodgkin Lymphoma
Phase 1 (1)
Advanced Solid Tumors and Non-Hodgkin Lymphoma
NCT05678998 · Werewolf Therapeutics, Inc.
2022-12-06 – 2025-02-05 · Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.